The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
AL amyloidosis: from molecular mechanisms to targeted therapies
Open accessAbstract
Systemic amyloidosis is caused by misfolding and extracellular deposition of circulating proteins as amyloid fibrils, resulting in the dysfunction of vital organs. The most common systemic amyloidosis, light-chain (AL) amyloidosis, is caused by misfolded light chains produced by a small, dangerous B-cell clone. The process of amyloid formation, organ targeting, and damage is multifaceted and, after disease initiation, the complexity of the downstream pathogenic cascade increases, rendering its control a challenge. Because of the progressive nature of the disease, early diagnosis to prevent end-stage organ damage is vital. Improving awareness and systematic use of biomarkers of organ damage in screening populations at risk may improve the still unsatisfactory diagnostic process. Amyloid imaging is now emerging as an important companion of biomarkers in formulating the diagnosis and prognosis and monitoring the effects of therapy. An accurate diagnosis is the basis for appropriate therapy that is risk-adapted and response-tailored. Effective treatments targeting the clone and rapidly and profoundly reducing the amyloid light chains have produced marked improvements in overall survival, making AL amyloidosis the most successful model of all amyloidoses. New therapies targeting the amyloid deposits are now under development, together with novel agents modulating light chain aggregation and proteotoxicity. The future of AL amyloidosis treatment is combination therapy and will require an innovative collaborative model for a rapid translation from bench to bedside with the ultimate aim of achieving a cure for this complex disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade
Chiti, F., & Dobson, C. M. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-045115 · Cited by 2,629 · cited 1×
“Interactions with the extracellular environment may result in proteolytic cleavage and binding to matrix components such as glycosaminoglycans and collagen, which serve as scaffolds and facilitate aggregation and fibril buildup.(1,3) This was recently confirmed by our group through in situ characterization of protein…”
Background
Cited by
Systemic immunoglobulin light chain amyloidosis
Merlini, G., Dispenzieri, A., Sanchorawala, V., Schönland, S. O., Palladini, G., Hawkins, P. N., & Gertz, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0034-3 · Cited by 552
Self-citationSystemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review
Gertz, M. A., & Dispenzieri, A. (2020) · JAMA · doi:10.1001/jama.2020.5493 · Cited by 366
Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications
Fermand, J.-P., Bridoux, F., Dispenzieri, A., Jaccard, A., Kyle, R. A., Leung, N., & Merlini, G. (2018) · Blood · doi:10.1182/blood-2018-04-839480 · Cited by 299
Self-citation
Metadata
- Authors
- Merlini, G.
- Venue
- Hematology
- Publisher
- American Society of Hematology
- Published
- 2017-12-08
- Volume
- 2017
- Issue
- 1
- Pages
- 1-12
- ISSN
- 1520-4383 (ISSN-L)
- 1520-4391
- OpenAlex
- W2774660741
- Cited by
- 200
- References
- 2
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: AL amyloidosis: from molecular mechanisms to targeted therapies. https://app.cochat.ai/papers/10.1182/asheducation-2017.1.1
- The paper
- Merlini, G. (2017). AL amyloidosis: from molecular mechanisms to targeted therapies. Hematology. https://doi.org/10.1182/asheducation-2017.1.1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.